arrow
S

Stephen Robinson

Sussex Cancer Centre
H指数:19
被引数:2,277

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Understanding the difference in symptoms and outcomes between glioblastoma patients diagnosed based on histological or molecular criteria: a retrospective cohort analysis from the Histo-Mol GBM collaborative

了解基于组织学或分子标准诊断的胶质母细胞瘤患者之间症状和结局的差异: 来自histo-mol GBM协作的回顾性队列分析

2026-01-080
OAAI
Defining the clinical target volume (CTV) in post-operative Thymic Epithelial Tumours - A clinical practice guide for UK Clinical Oncologists.

定义术后胸腺上皮肿瘤的临床靶区(CTV)——英国临床肿瘤学家的临床实践指南。

2025-12-090
OAAI
INTEGRATED MULTI-OMICS AND MULTI-SPECTRAL PROFILING OF PLASMA EXTRACELLULAR VESICLES REVEALS HIGHLY ACCURATE LIQUID BIOPSY BIOMARKERS FOR GLIOMA DIAGNOSIS.

整合多组学和多重光谱分析血浆外泌体,揭示出高度准确的胶质瘤诊断液体活检生物标志物。

2025-10-010
OA
INVESTIGATING SHORT TERM (<6 MONTHS) SURVIVORS OF GLIOBLASTOMA - AN ANALYSIS OF THE HISTO-MOL GBM COLLABORATIVE DATABASE.

调查短期(<6个月)胶质母细胞瘤生存者——基于Histology-Molecular GBM Collaborative数据库的分析。

2025-10-010
OAAI
DEVELOPING AN EXTRACELLULAR VESICLE-BASED MULTI-OMIC LIQUID BIOPSY BIOMARKER SIGNATURE OF GLIOMA USING SAMPLES FROM THE GENOMICS ENGLAND BIOBANK

开发一种基于细胞外囊泡的多组学液体活检生物标志物签名,用于胶质瘤,使用来自基因组学英格兰生物样本库的样本

2025-09-020
OAAI
THE LANDSCAPE OF SECOND LINE (AND BEYOND) TREATMENTS FOR GLIOBLASTOMA (IDH WILDTYPE) IN THE UK IN 2021: AN UPDATE FROM THE HISTO-MOL GBM COLLABORATIVE

2021年英国IDH野生型胶质母细胞瘤的二线(及以上)治疗方案概况:来自Histo-Mol GBM Collaborative的更新

2025-09-020
OAAI
Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy Consortium

脑肿瘤液体活检方法中的前分析变量和检测物:RANO Group和Brain Liquid Biopsy Consortium的综述与建议

2025-08-010
PRE
First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study

SCLC的一线化学免疫疗法: 一项两国现实世界研究的结果

2025-01-010
OA
GLIOBLASTOMA IN OLDER ADULTS, A NEED FOR BOLDER TREATMENT IN SELECTED PATIENTS?
2024-10-170
PRE
MOLECULAR GLIOBLASTOMAS - BETTER PROGNOSIS AFTER CORRECTING FOR TREATMENT DIFFERENCES
2024-10-170
PRE
GLIOBLASTOMA IN 2021, DEVELOPING A LARGE INDIVIDUAL PATIENT DATABASE TO INVESTIGATE OUTCOMES AND TREATMENT PATTERNS
2024-10-170
PRE
Management Approaches in WHO Grade III Meningioma: A National Oncology Trainees' Collaborative for Healthcare Research (NOTCH) UK Multi-Centre Retrospective Study
2024-09-011
PRE